We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Scancell Holdings Plc | SCLP | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 9.60 | 08:00:21 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 9.60 | 9.38 | 9.60 | 9.60 | 9.60 |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
| Top Posts |
|---|
Posted at 27/4/2024 16:38 by inanaco ""It is simply not true to say that the probability of success in future trials will always be higher than the objective response rate from the current trial. I can't understand why you would think that."" bermudastands to reason ... because the next trial to be a success only needs a lower number ie 70% than the proven 85% of 43 (subject to that being maintained) gives you a huge margin of error thus the Probability has to be higher than 85 if it is not show the maths please at this stage i cannot predict a phase 3 ... i dont have the data what i am trying to do is work out from what we know what is required to give investors some sort of head light going forward but what i will say ......... it will get approved if the ORR rate is maintained and the patients cancer continue to shrink after each scan as per the plots |
Posted at 26/4/2024 15:28 by rogerbridge The problem with Scancell is that the PR is non existent.We have been told that Moderna will.be in trouble if the Scancell technology proves to be as or more effective. The difference in cost will be substantial and there is the ease of use issue. Investors have no idea of what talks are happening behind closed doors. We have been told there are four or five companies interested in some products. Time will tell, but if Scancell was listed on the NASDAQ, the share price would be in multiples of what it is today. |
Posted at 24/4/2024 11:01 by sci102 Price sensitive or not, respect your investors. |
Posted at 22/4/2024 08:18 by bermudashorts nigel,We've seen endless debate on whether Scancell gets to a multi billion dollar valuation or is the next BioNTech, but I honestly don't think that's the investment case here. It certainly isn't for me. There are a number of short to medium term events that could/should provide opportunites for retial investors. Some are more significant than others but the cumulative effect should bring about a change in sentiment and current valuation. Let me know if you want me to list them. The redemption date of Redmile's CLNs and the need to fund the forthcoming phase II/II SCIB1 trial will be at the forefront of the BOD's mind when deciding strategy. Even if Redmile are prepared to extend again, Scancell will need to attract more institutional investment and ideally some good quality specialist funds. This will no doubt be taken as a negative comment by some, but it's not. It means that Scancell absolutely have to deliver the planned inflection points on time and the focus will very much be on increasing their valuation. I'm not sure that's always been the case in the past. On a more general note, the cancer vaccine field is finally starting to gain some traction and much will depend on whether that movement gains momentum and major oncology players decide they need a vaccine in their pipeline. We need to see some big success stories and early signs of M&A activity. So I hope for a series of positive announcemnts for the rest of this year and some major events in 2025. In terms of valuation, I think we've seen some sensible predictions on lse but it will depend entirely on the point I make in the above paragraph and of course those trial results. |
Posted at 17/4/2024 19:18 by chilltime Dear LindyYou are hear-by invited to update your information starved shareholders. Confirmatory scans have been and gone with all well past the 3rd scan, and 3 patients missing any at all. From the hints of excitement in news and rumour control it seems that all is going very well indeed, but as in science (with this current market), it’s not much use without the details, investors want details. Obviously the nomad considers each event attendance as material news, but it has been shown to not be price sensitive. TIA |
Posted at 10/4/2024 22:07 by marcusl2 London markets are broken and closed, says pharma bossE-therapeutics joins the stampede of biotech companies quitting Aim James Titcomb 10 April 2024 • 6:49pm Ali Mortazavi Chief executive Ali Mortazivi says delisting the company comes with 'sadness and great worry' for UK markets A British pharmaceuticals company has criticised London’s stock markets for being “completely broken and closed” after announcing plans to de-list and pursue a potential flotation in New York. Ali Mortazavi, chief executive of E-therapeutics, said “urgent reform and action was needed” after accusing British investors of failing to back innovative companies. E-therapeutics said it would de-list, 17 years after floating on Aim, London’s junior market, as part of a £29m fundraising from existing investors. It said it would “explore the option of listing on [New York’s] Nasdaq in due course”. Writing on X, formerly Twitter, Mr Mortazavi said: “My overriding feeling in delisting [the company] is one of sadness and great worry. “To be clear, the UK markets are not just illiquid, they’re completely broken and closed. The situation is worse for small growth companies (in particular biotech) but even sizeable companies such as Shell and many others are saying the same thing.” |
Posted at 09/4/2024 09:58 by sci102 Open label and it's been 5 months since the last update. Previously they gave an update in September and then in November. They do have the data. Why they didn't present it at AACR when it was a golden opportunity is beyond me. I certainly don't think that they presented price sensitive and previously unannounced data at AACR, yet they did not RNS the update.The irony is they did RNS that they are attending all these conferences the past 2 months, but obviously they don't think the investors should know more than that. This is not a comment on regulatory requirements, it is about the stance of the company towards investors. |
Posted at 08/4/2024 07:12 by sci102 So once again scancell shows that something is not functioning properly with their IR team. Either they did not prepare the RNS beforehand so that it could be published this morning since they already knew what they were going to present OR decided again to leave investors in the dark whether they did present new data (that they surely have in their hands) or not.Again, this is not a comment on regulatory requirements, but about their stance towards investors. We will know the answer later today or tomorrow morning. |
Posted at 13/2/2024 18:27 by sci102 Not important in the grant scheme, but since the company used to give regular updates on scope, they should have given one at the previous presentation. And trust that at least their committed and experienced investors understand how clinical development works. Nobody that matters would care if for example at a particular snapshot the orr was 75% or whatever. Or at least they should realise that many would wonder about it in absence of updates anyway. No change of position from me, but I get why some opportunistic "casual" investors may be taking a step back. |
Posted at 01/12/2023 10:26 by bermudashorts SC102Redmile and Vulpes' contribution to the total amount raised was less than £3.5m. The placing has been priced at a level to attract sufficient funds from other investors to meet the total required. Given the fact that it was so heavily oversubscribed, you have to wonder whether they could have raised at a slightly higher level, but it's a balancing act. Price it too high and investors will walk away, too low and you have diluted more than you needed to. For sure though they will have sounded out the market in advance and set the price accordingly. The RNS this morning mentioned that new specialist life sciences investors had invested, hope we find out who they are as this will give some clue as to the direction of travel here. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
